ReShape Lifesciences Inc. - רווח נקי למניה בארבעת הרבעונים האחרונים RSLS

ReShape Lifesciences (RSLS) dominates the minimally invasive obesity therapy segment by leveraging its recognized Lap-Band technology. The annual EPS growth rate over the last 12 months reflects profit dynamics, where 76.80 indicates the current value of the metric. However, stringent FDA oversight and patent protections create high barriers to entry, while liquidity shortages and small sales scale hinder the company's path to break-even.

Conservative asset selection requires minimizing fundamental risks through the analysis of profit dynamics. This indicator captures the percentage change in net income per share over twelve months, separating market noise from a sustainable trend. For ReShape Lifesciences (RSLS), this growth is driven by the robotization of equipment assembly, which reduces manual labor costs. By analyzing the annual volatility of TTM net income per share, an investor assesses the efficiency of automation. Peak values here signal the risk of a subsequent correction.